Home › Kanser ng Endometrium › Texas › Fort Worth
Pag-aaral pangklinika para sa Kanser ng Endometrium sa Fort Worth, TX
Isang pag-aaral para sa Kanser ng Endometrium ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Fort Worth. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- START Center for Clinical Research, Fort Worth
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Nagre-recruitPhase 2
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Nagre-recruitPhase 1/2
- START Dallas Fort Worth, Fort Worth
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Nagre-recruitPhase 3
- Texas Oncology - DFW ( Site 8004), Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Start - Dfw, Fort Worth
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Nagre-recruitPhase 3
- USOR - Texas Oncology - Dallas Fort Worth (DFW), Fort Worth
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Nagre-recruitPhase 3
- Research Site, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- START Center for Cancer Research - Texas, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Nagre-recruitPhase 1
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Nagre-recruitPhase 1
- START Dallas Fort Worth, LLC, Fort Worth
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Nagre-recruitPhase 2/3
- Texas Oncology-Fort Worth Cancer Center, Fort Worth
Pag-aaral para sa Kanser ng Endometrium sa ibang lungsod
- Houston, TX68 pag-aaral
- New York City, NY52 pag-aaral
- Boston, MA50 pag-aaral
- Arlington, VA39 pag-aaral
- Nashville, TN38 pag-aaral
- Los Angeles, CA34 pag-aaral
- St. Louis, MO29 pag-aaral
- Philadelphia, PA28 pag-aaral
- San Antonio, TX27 pag-aaral
- Chicago, IL25 pag-aaral
- Columbus, OH25 pag-aaral
- Queens, NY25 pag-aaral
Iba pang pag-aaral sa Fort Worth
- Non-Small Cell Lung Cancer18 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Kanser sa Suso11 pag-aaral
- Kanser (lahat ng uri)9 pag-aaral
- Kanser sa Prostate9 pag-aaral
- Pagkabigo ng Puso7 pag-aaral
- Colorectal Cancer7 pag-aaral
- Triple-Negative Breast Cancer7 pag-aaral
- Metastatic Cancer7 pag-aaral
- Kanser sa Bato (Renal Cell Carcinoma)7 pag-aaral
- Ulcerative Colitis7 pag-aaral
- Degenerasyon ng Macula7 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.